Rhenman & Partners Asset Management Ab Revance Therapeutics, Inc. Transaction History

Rhenman & Partners Asset Management Ab

$1.2 Billion
Q3 2024

19 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	BUY	$4.65 - $9.31 $1.05 Million - $2.1 Million	225,835 Added 47.46%	701,707 $3.45 Million
Q4 2023 Feb 13, 2024	BUY	$5.81 - $11.2 $663,461 - $1.28 Million	114,193 Added 31.57%	475,872 $4.18 Million
Q3 2023 Nov 13, 2023	BUY	$11.47 - $25.07 $2.74 Million - $5.98 Million	238,679 Added 194.05%	361,679 $4.15 Million
Q2 2023 Aug 11, 2023	SELL	$24.7 - $37.61 $2.64 Million - $4.02 Million	-107,000 Reduced 46.52%	123,000 $3.11 Million
Q1 2023 May 11, 2023	SELL	$18.36 - $35.27 $3.82 Million - $7.34 Million	-208,000 Reduced 47.49%	230,000 $7.41 Million
Q4 2022 Feb 13, 2023	BUY	$18.32 - $30.66 $916,000 - $1.53 Million	50,000 Added 12.89%	438,000 $8.09 Million
Q3 2022 Nov 14, 2022	SELL	$14.33 - $28.47 $888,460 - $1.77 Million	-62,000 Reduced 13.78%	388,000 $8.66 Million
Q2 2022 Aug 12, 2022	BUY	$11.52 - $20.4 $2.9 Million - $5.13 Million	251,642 Added 126.86%	450,000 $6.22 Million
Q1 2022 May 13, 2022	BUY	$12.36 - $20.31 $2.45 Million - $4.03 Million	198,358 New	198,358 $3.87 Million
Q4 2021 Feb 11, 2022	SELL	$12.46 - $27.87 $3.99 Million - $8.92 Million	-320,000 Closed	0 $0
Q3 2021 Nov 12, 2021	BUY	$25.78 - $33.21 $1.29 Million - $1.66 Million	50,000 Added 18.52%	320,000 $8.92 Million
Q2 2021 Aug 13, 2021	BUY	$26.8 - $31.84 $1.34 Million - $1.59 Million	50,000 Added 22.73%	270,000 $8 Million
Q1 2020 Apr 16, 2020	SELL	$12.46 - $27.81 $373,800 - $834,300	-30,000 Reduced 12.0%	220,000 $3.26 Million
Q4 2019 Jan 17, 2020	BUY	$11.66 - $20.15 $887,127 - $1.53 Million	76,083 Added 43.75%	250,000 $4.06 Million
Q3 2019 Oct 16, 2019	SELL	$10.22 - $14.5 $196,878 - $279,328	-19,264 Reduced 9.97%	173,917 $2.26 Million
Q4 2018 Feb 05, 2019	SELL	$18.06 - $24.96 $180,600 - $249,600	-10,000 Reduced 4.92%	193,181 $3.89 Million
Q1 2018 Apr 11, 2018	BUY	$29.15 - $37.4 $600,519 - $770,477	20,601 Added 11.28%	203,181 $6.26 Million
Q4 2017 Jan 19, 2018	SELL	$24.55 - $36.3 $1.57 Million - $2.32 Million	-63,820 Reduced 25.9%	182,580 $6.53 Million
Q3 2017 Oct 13, 2017	BUY	$22.55 - $28.1 $5.56 Million - $6.92 Million	246,400	246,400 $6.79 Million

Others Institutions Holding RVNC

# of Institutions

234

Shares Held

82.8M

Call Options Held

680K

Put Options Held

896K

Black Rock Inc. New York, NY

8.57M
Shares

$22 Million
0.0% of portfolio
Vanguard Group Inc Valley Forge, PA

5.73M
Shares

$14.7 Million
0.0% of portfolio
Franklin Resources Inc San Mateo, CA

4.78M
Shares

$12.3 Million
0.0% of portfolio
Fil LTD Hamilton, D0

4.19M
Shares

$10.8 Million
0.01% of portfolio
Alpine Associates Management Inc. Englewood Cliffs, NJ

4.16M
Shares

$10.7 Million
0.49% of portfolio

View Full List

About Revance Therapeutics, Inc.

Ticker RVNC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 82,305,696
Market Cap $212M
Description
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials fo...

More about RVNC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhenman & Partners Asset Management Ab, based on Form 13F filings with the SEC.

News

Stay updated on Rhenman & Partners Asset Management Ab with notifications on news.

Account